326 related articles for article (PubMed ID: 37685358)
21. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
22. NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease.
Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk A; Filosso PL; Wójcik-Giertuga M; Rydel M; Zielińska-Leś I; Walter A; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Jamidar P; Ziora D; Czyżewski D; Kos-Kudła B; Ćwikła J
Neuroendocrinology; 2019; 108(3):219-231. PubMed ID: 30654372
[TBL] [Abstract][Full Text] [Related]
23. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
[TBL] [Abstract][Full Text] [Related]
24. Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?
Giannetta E; La Salvia A; Rizza L; Muscogiuri G; Campione S; Pozza C; Colao AAL; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():672499. PubMed ID: 34367064
[TBL] [Abstract][Full Text] [Related]
25. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
Marotta V; Zatelli MC; Sciammarella C; Ambrosio MR; Bondanelli M; Colao A; Faggiano A
Endocr Relat Cancer; 2018 Jan; 25(1):R11-R29. PubMed ID: 29066503
[TBL] [Abstract][Full Text] [Related]
26. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Malczewska A; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):895-906. PubMed ID: 31838581
[TBL] [Abstract][Full Text] [Related]
27. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
[TBL] [Abstract][Full Text] [Related]
28. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of
Bodei L; Raj N; Do RK; Mauguen A; Krebs S; Reidy-Lagunes D; Schöder H
J Nucl Med; 2023 Apr; 64(4):567-573. PubMed ID: 36396457
[TBL] [Abstract][Full Text] [Related]
29. Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors.
Partelli S; Andreasi V; Muffatti F; Schiavo Lena M; Falconi M
Ann Surg Oncol; 2020 Oct; 27(10):3928-3936. PubMed ID: 32253675
[TBL] [Abstract][Full Text] [Related]
30. The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK.
Malczewska A; Procner A; Walter A; Kusnierz K; Zajecki W; Aslanian H; Kos-Kudla B
BMC Gastroenterol; 2020 Jul; 20(1):235. PubMed ID: 32703157
[TBL] [Abstract][Full Text] [Related]
31. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.
van Treijen MJC; Korse CM; van Leeuwaarde RS; Saveur LJ; Vriens MR; Verbeek WHM; Tesselaar MET; Valk GD
Front Endocrinol (Lausanne); 2018; 9():740. PubMed ID: 30564197
[No Abstract] [Full Text] [Related]
32. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.
Modlin IM; Kidd M; Frilling A; Falconi M; Filosso PL; Malczewska A; Kitz A
Ann Surg; 2021 Sep; 274(3):481-490. PubMed ID: 34183517
[TBL] [Abstract][Full Text] [Related]
33. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis.
Melone V; Salvati A; Palumbo D; Giurato G; Nassa G; Rizzo F; Palo L; Giordano A; Incoronato M; Vitale M; Mian C; Di Biase I; Cristiano S; Narciso V; Cantile M; Di Mauro A; Tatangelo F; Tafuto S; Modica R; Pivonello C; Salvatore M; Colao A; Weisz A; Tarallo R
J Transl Med; 2022 Jul; 20(1):306. PubMed ID: 35794609
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection.
Laskaratos FM; Liu M; Malczewska A; Ogunbiyi O; Watkins J; Luong TV; Mandair D; Caplin M; Toumpanakis C
Endocrine; 2020 Aug; 69(2):430-440. PubMed ID: 32291735
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review.
Kalligeros M; Diamantopoulos L; Toumpanakis C
Biology (Basel); 2021 Sep; 10(10):. PubMed ID: 34681049
[TBL] [Abstract][Full Text] [Related]
36. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
37. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers.
Herrera-Martínez AD; Hofland LJ; Gálvez Moreno MA; Castaño JP; de Herder WW; Feelders RA
Endocr Relat Cancer; 2019 Mar; 26(3):R157-R179. PubMed ID: 30615596
[TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.
Öberg K; Califano A; Strosberg JR; Ma S; Pape U; Bodei L; Kaltsas G; Toumpanakis C; Goldenring JR; Frilling A; Paulson S
Ann Oncol; 2020 Feb; 31(2):202-212. PubMed ID: 31959337
[TBL] [Abstract][Full Text] [Related]
39. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
[TBL] [Abstract][Full Text] [Related]
40. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
